Identification, diagnosis and control of patients with abdominal obesity and cardiovascular and metabolic risk factors;Identificación, diagnóstico y control del paciente con obesidad abdominal y factores de riesgo cardiovascular y metabólico

Medicina Clinica

Volumn 128, Issue 11, 2007, Pages 429-437

  Moreno, Basilio ^a   Casanueva, Felipe ^b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL OBESITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; HUMAN; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT;

EID: 34247483591     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13100347     Document Type: Conference Paper

References (115)

1. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculus disease. Am J Clin Nutr. 1956;4:20-34.
2. Pais PS. Early intervention and prevention of myocardial infarction. J Hypertens Suppl. 2006;24:S25-S30.
3. Sociedad Española para el Estudio de la Obesidad (SEEDO). Consenso SEEDO'2000 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Med Clin (Barc). 2000;115:587-97.
4. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994;17:961-9.
5. Sharma AM. The obese patient with diabetes mellitus: from research targets to treatment options. Am J Med. 2006;119 Suppl 1:17-23.
6. Schaffler A, Scholmerich J, Buchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue-emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2:273-80.
7. Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin HM, et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab. 2000;85:1151-8.
8. Sartor BM, Dickey RP. Polycystic ovarian syndrome and the metabolic syndrome. Am J Med Sci. 2005;330:336-42.
9. Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab. 1999;84:137-44.
10. Faria AN, Ribeiro Filho FF, Gouveia Ferreira SR, Zanella MT. Impact of visceral fat on blood pressure and insulin sensitivity in hypertensive obese women. Obes Res. 2002;10:1203-6.
11. Amer P. Differences in lipolysis between human subcutaneous and omental adipose tissues. Ann Med. 1995;27:435-8.
12. Lam TK, Carpentier A, Lewis GF, Van de Werve G, Fantus G, Giacca A. Mechanisms of the free fatty acid-induced increase in hepatic glucose production. Am J Physiol Endocrinol Metab. 2003;284:E863-E73.
13. Jenssen MD. Adipose tissue as an endocrine organ: implications of its distribution on free fatty acid metabolism. Eur Heart J. 2006;8 Suppl B:13-9.
14. Nielsen S, Guo Z, Johnson CM, Hensrud D, Jensen MD. Splacnic lipolysis in human obesity. J Clin Invest. 2004;113:1582-8.
15. Ahima R, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab. 2000;11:327-32.
16. Ferroni P, Basili S, Falco A, Davi G. Inflammation, insulin resistance, and obesity. Curr Atheroscler Rep. 2004;6:424-31.
17. Tataranni PA. Relationship between subclinical inflammation, obesity, diabetes and related disorders. Drug Discov Today: Disease Mechanisms. 2005. p. 2303-6.
18. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-56.
19. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-607.
20. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med. 1998;15:539-53.
21. European Group for the Study of Insulin Resistance (EGIR). Comment on the provisional report from the WHO consultation. Diabet Med. 1999;6:442-3.
22. Grundy SM, Brewer HB, Cleeman Jl, Smith SC, Lenfant C. Definition of metabolic syndrome. Report of The National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-8.
23. International Diabetes Federation. The IDF Consensus Worldwide definition of the metabolic syndrome. Disponible en: www.idf.org
24. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289-304.
25. Reaven GM. The metabolic syndrome: requiescat in pace. Clin Chem. 2005;51:931-8.
26. Despre's JP. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk. Eur Heart J. 2006;8 Suppl B:4-12.
27. Institute de Salud Carlos III. Disponible en: http://www.isciii.es/ htdocs/centros/epidemiologia/epienfcardioTabla1.jsp
28. Ruiz-Ramos M, Escolar-Pujolar A, Mayoral-Sánchez E, Corral-San Laureano F, Fernández-Fernández I. Diabetes mellitus en Españo: índices de mortalidad, prevalencia, impacto y costes. Gac Sanit. 2006;20 Supl 1:15-24.
29. Tranche S, Galgo A, Mundet X, Sánchez-Zamorano MA, Karen AP. Cardiovascular risk factors in type 2 diabetic patients: multifactorial intervention in primary care. Kidney Int Suppl. 2005;93:S55-S62.
30. Cosín Aguilar J, Rodríguez Padial L, Hernándiz Martínez A, Aristegui Urrestarazu R, Masramon Morell X, Armada Peláez B, et al. Riesgo cardiovascular en diabetes mellitus e hipertensidn arterial en España. Estudio CORONARIA. Med Clin (Barc). 2006;127:126-32.
31. Segura J, Campo C, Gil P, Roldán C, Vigil L, Rodicio JL, et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol. 2004;15:1616-22.
32. Aranceta J, Pérez Rodrigo C, Serra Majem L, Ribas Barba L, Quiles Izquierdo J, Vioque J, et al. Grupo colaborativo para el Estudio de la Obesidad en Espãa. Prevalencia de obesidad en España: resultados del Estudio SEEDO 2000. Med Clin (Barc). 2003;120:608-12.
33. Aranceta-Bartrina J, Serra-Majem L, Foz-Sala M, Moreno-Esteban B y Grupo Colaborativo SEEDO. Prevalencia de obesidad en España. Med Clin (Barc). 2005;125:460-6.
34. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004;27:2444-9.
35. Ascaso JF, Romero P, Real JT, Lorente RI, Martínez-Vails J, Carmena R. Abdominal obesity, insulin resistance, and metabolic syndrome in a Southern European population. Eur J Intern Med. 2003;14:101-6.
36. Balkau B, Haffner S, Després JP. The International Day for the Evaluation of Abdominal Obesity (IDEA) survey: prevalence of abdominal obesity in primary care physician practice. ACC Congress; 2006, marzo 26.
37. Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of insulin resistance syndrome. Diabetes Metab. 2002;28:364-76.
38. Gabriel R, Serrano-Ríos M, Pladevall M. Relationships between visceral adiposity, body size and fat distribution indexes with fasting insulin levels in the Spanish general population. Can J Cardiol. 1997;13 Suppl B:280.
39. Álvarez EE, Ribas L, Serra L. Prevalencia del síndrome metabólico en la población de la Comunidad Canaria. Med Clin (Barc). 2003;120:172-4.
40. Lorenzo C, Serrano-Ríos M, Martínez-Larrad MT, Gabriel R, Williams K, Gómez-Gerique JA, et al. Central adiposity detemines prevalence difference of the metabolic syndrome. Obes Res. 2003;11:1480-7.
41. Martínez-Larrad MT, Fernández-Pérez C, González-Sánchez JL, López A, Fernández- Álvarez J, Riviriego J, et al. Grupo de Atención Primaria de Segovia. Prevalencia del síndrome metabólico (criterios ATP-III). Estudio poblacional en áreas rural y urbana de la provincia de Segovia. Med Clin (Barc). 2005;125:481-6.
42. Soto A, Bellido D, Buño M. Prevalencia del sĩndrome metabólico en una población de pacientes con sobrepeso y obesidad. Endocrin Nutria 2005;52:391-6.
43. Sánchez-Chaparro MA, Román-García J, Calvo-Bonacho E, Gómez-Larios T, Fernández-Meseguer A, Sainz-Gutiérrez J, et al. Grupo de Estudio del Plan de Prevención del Riesgo Cardiovascular de Ibermutuamur. Prevalencia de factores de riesgo vascular en la población laboral española. Rev Esp Cardiol. 2006;59:421-30.
44. Sánchez-Chaparro MA, Román-García J, Calvo-Bonacho E, Gómez-Larios T, Fernández-Meseguer A, Sainz-Gutiérrez J, et al. Grupo de Estudio del Plan de Prevención del Riesgo Cardiovascular de Ibermutuamur). Prevalencia del síndrome metabólico en la población laboral española. Clin Invest Arterioscl. 2005;17 Supl 1:32-3.
45. Alegría E, Cordero A, Laclaustra M, Grima A, León M, Casanovas JA, et al. Prevalencia del síndrome metabólico en la población laboral española. Rev Esp Cardiol. 2005;58:797-806.
46. Rodilla E, García L, Merino C, Costa JA, González C, Pascual JM. Impacto del síndrome metabólico en el control de la presión arterial y de la dislipemia. Med Clin (Barc). 2004;123:601-5.
47. De la Sierra A, Romero R, Bonet J, Pérez M, López JS, Ravella R, et al. Investigadores del Estudio ESOPOH. Prevalencia y características generates del síndrome metabólico en población hipertensa en España. Med Clin (Barc). 2006;126:406-9.
48. Hernández A, Riera C, Solá E, Oliver MJ, Martínez ML, Morillas C, et al. Prevalencia del síndrome metabólico entre pacientes con cardiopatía isquémica. Med Clin (Barc). 2003;121:204-8.
49. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-9.
50. Subirats E, Vila E, Vila T, Vallescar R. Prevalencia de factores de riesgo cardiovascular en una población del norte de Cataluña: La Cerdaña. An Med Int. 1997;14:220-5.
51. García Alegría JJ, Dueñas RM, Gascón F. Factores de riesgo cardiovascular en la población adulta del Valle de los Pedroches (Córdoba). Clin Invest Arteioscl. 1991;3:97-106.
52. Capilla Morera A. Prevalencia de los factores de riesgo cardiovascular en el Centra de Salud de Pozuelo (Madrid), durante 1998. Clin Invest Arterioscl. 1991;3:107-12.
53. Marín A, Medrano MJ, González J, Pintado H, Compaired V, Barcena M, et al. Risk of ischaemic heart disease and acute myocardial infarction in a Spanish population: observational prospective study in a primary care setting. BMC Public Health. 2006;6:38.
54. Medrano MJ, Cerrato E, Boix R, Delgado-Rodríguez M. Factores de riesgo cardiovascular en la población española: metaanálisis de estudios transversales. Med Clin (Barc). 2005;124:606-12.
55. Rose G. The strategy of preventive medicine. Oxford, New York: Oxford University Press; 1992.
56. Manuel DG, Lim J, Tanuseputro P, Anderson GM, Alter DA, Laupacis A, et al. Revisiting Rose: strategies for reducing coronary heart disease. BMJ. 2006;332:659-62.
57. Jackson R, Lawes CMM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's cardiovascular risk. Lancet. 2005;365:434-41.
58. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts) Executive summary. European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardio Prev Rev. 2003;10 Suppl 1:1-78.
59. Lobos JM, Brotons C. Nuevas estrategias en prevencidn cardiovascular. Aten Primaria. 2004;34:389-91.
60. Brotons C, Royo-Bordonada M, Alvarez-Sala L, Armario P, Artigao R, Conthe P, et al. Comité Español Interdisciplinary para la Prevención Cardiovascular (CEIPC). Adaptación española de la guía europea de prevención cardiovascular. Rev Esp Salud Pública. 2004;78:435-8.
61. Grundy SM, Pasternak RC, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 1999;34:1348-59.
62. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47.
63. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.
64. European Society of Cardiology. Score Risk Charts. Disponible en: wwwescardioorg/iniciatives/prevention/SCORE+Risk+Chartshtm
65. Marrugat J, Solanas P, D'Agostino R, Sullivan L, Ordovas J, Corddn F, et al. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. Rev Esp Cardiol. 2003;56:253-61.
66. Aranceta J, Pérez Rodrigo C, Foz Sala M, Mantilla T, Serra Majem L, Moreno B, et al. Tablas de evaluación del riesgo coronario adaptadas a la población española. Estudio DORICA. Med Clin (Barc). 2004;123: 686-91.
67. Adult Treatment Panel III. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 2001;285:2486-97.
68. Grundy SM, Cleeman JI, Merz NB, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39.
69. Stevens J, Cain J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the assotiation between body-mass index and mortality. N Engl J Med. 1998;338:1-7.
70. Peeters A, Barendregt JJ, Willenkens F, Mackenbach JP, AI Mamun A, Bonneux L. NEDCOM, the Netherlands Epidemiology and Demography Compression of Morbidity Research Group. Obesity in adulthood and its consequences for life expectancy: A life-table analysis. Ann Intern Med. 2003;138:24-32.
71. Calle EE, Thun MJ, Petrelli JM, Rodríguez C, Heat CW. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341:1097-105.
72. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA. 2005;293:1861-7.
73. McGee DL. Diverse Populations Collaboration. Body mass index and mortality: a meta-analysis based on person-level data from twenty-six observational studies. Ann Epidemiol. 2005;15:87-97.
74. González-Huix F, Fernández-Real. Obesidad abdominal: ¿es útil la relación cintura/cadera? Med Clin (Barc). 2000;114:417-8.
75. Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol. 1995;141:1117-27.
76. Folsom AR, Stevens J, Schreiner PJ, McGovern PG. Body mass index, waist/hip ratio, and coronary heart disease incidence in African Americans and whites. Atherosclerosis Risk in Communities Study Investigators. Am J Epidemiol. 1998;148:1187-94.
77. Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Björntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J. 1984;288:1401-4.
78. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjöström L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J. 1984;289:1257-61.
79. Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, et al. Abdominal adiposity and coronary heart disease in women. JAMA. 1998;280:1843-8.
80. Lakka HM, Lakka TA, Toumilehto J, Salonen JT. Abdominal obestity is associated with increased risk of acute coronary events in men. Eur Heart J. 2002;23:706-13.
81. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-16.
82. Higgins M, Kannel W, Garrison R, Pinsky J, Stokes J. Hazards of obesity - the Framingham experience. Acta Med Scand Suppl. 1988;723:23-36.
83. Hoefle G, Saely CH, Aczel S, Benzer W, Marte T, Langer P, et al. Impact of total and central obesity on vascular mortality in patients undergoing coronary angiography. Int J Obes. 2005;29:785-91.
84. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-52.
85. Empana JP, Ducimetiere P, Charles MA, Jouven X. Sagittal abdominal diameter and risk of sudden death in asymptomatic middle-aged men: the Paris Prospective Study I. Circulation. 2004;110:2781-5.
86. Carey VJ, Walters EE, Colditz GA, Solomon CG, Willett WC, Rosner BA, et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. Am J Epidemiol. 1997; 145:614-9.
87. Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB. Comparison of abdominal adiposity and overall dbesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr. 2005;81:555-63.
88. Saely CH, Aczel S, Marte T, Langer P, Hoefle G, Drexel H, et al. The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab. 2005;90:5698-703.
89. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002;156:1070-7.
90. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95:69-75.
91. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Almeras N, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation. 2000;102:179-84.
92. Tanko LB, Bagger YZ, Qin G, Alexandersen P, Larsen PJ, Christiansen C, et al. Enlarged waist combined with elevated triglycerides is strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation. 2005;111:1883-90.
93. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881-7.
94. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-34.
95. Evans JMM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes mellitus and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ. 2002;324:939-42.
96. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non diabetic people: a population based retrospective cohort study. Lancet. 2006;368:29-36.
97. Haffner SM. Abdominal obesity, insulin resistance, and cardiovascular risk in pre-diabetes and type 2 diabetes. Eur Heart J. 2006;8 Suppl B:20-5.
98. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation. 2004;110:1251-7.
99. Lemieux I, Pascot A, Prud'homme D, Alméras N, Bogaty P, Nadeau A, et al. Elevated C-reactive protein. Another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol. 2001;21:961-7.
100. Diamant M, Lamb HJ, Van de Ree MA, Endert EL, Groeneveld Y, Bots ML, et al. The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers in uncomplicated type 2 diabetes. J Clin Endocrinol Metab. 2005;90:1495-501.
101. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-7.
102. Guidelines Committee 2003 European Society of Hypertension-European Society of Cardiology. Guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-53.
103. Sjöström L. A computer-tomography based multicompartment body composition technique and anthropometric predictions of lean body mass, total and subcutaneous adipose tissue. Int J Obes. 1991; 15:19-30.
104. Martínez Olmos MA, Bellido Guerrero D, Blay Cortes V. Métodos de valoración de la distribución de la grasa corporal en el paciente obeso. Rev Esp Obes. 2004;2:42-9.
105. Fuller NJ, Hardingham CR, Graves M, Screaton N, Dixon AK, Ward LC, et al. Predicting composition of leg sections with anthropometry and bioelectrical impedance analysis, using magnetic resonance imaging as reference. Clin Sci. 1999;96:647-57.
106. Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994;73:460-9.
107. Kotani K, Tokunaga K, Fujioka S, Kobatake T, Keno Y, Yoshida S, et al. Sexual dimorphism of age-related changes in whole-body fat distribution in obese. Int J Obes Relat Metab Disord. 1994;18:207-2.
108. Kuk J, Lee SJ, Heymsfield SB, Ross R. Waist circumference and abdominal adipose tissue distribution: influence of age and sex. Am J Clin Nutr. 2005;81:1330-4.
109. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity related health risk. Am J Clin Nutr. 2004;79:379-84.
110. Bigaard J, Tjonneland A, Thomsen BL, Overvad K, Heitmann BL, Sorensen TIA. Waist circumference, BMI, smoking, and mortality in middle-aged men and women. Obes Res. 2003;11:895-903.
111. Ardern CI, Janssen I, Ross R, Katzmarzyk PT. Development of health-related waist circumference thresholds within BMI categories. Obes Res. 2004;12:1094-103.
112. Wang J, Thornton JC, Bari S, Williamson B, Gallagher D, Heymsfield SB, et al. Comparisons of waist circumferences measured at 4 sites. Am J Clin Nutr. 2003;77:379-84.
113. Dobbelsteyn CJ, Joffres MR, MacLean DR, Flowerdew G. A comparative evaluation of waist circumference, waist-to-hip ratio and body mass index as indicators of cardiovascular risk factors. The Canadian Heart Health Surveys. Int J Obes Relat Metab Disord. 2001;25:652-61.
114. Bigaard J, Thomsen BL, Tjonneland A. Does waist circumference alone explain obesity-related health risk? Am J Clin Nutr. 2004;80:790-1.
115. Wang J. Standardization of waist circumference reference data Am J Clin Nutr. 2006;83:3-4.